These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 17089166

  • 1. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E.
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
    Ciomei M, Croci V, Ciavolella A, Ballinari D, Pesenti E.
    Clin Cancer Res; 2006 May 01; 12(9):2856-61. PubMed ID: 16675581
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

  • 4. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y.
    Cancer Chemother Pharmacol; 2006 May 01; 57(5):693-702. PubMed ID: 16362295
    [Abstract] [Full Text] [Related]

  • 6. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

  • 7. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B, Komarnitsky P, Miller GT, Amedio J, Wallner BP.
    Anticancer Drugs; 2012 Feb 01; 23(2):173-84. PubMed ID: 22027537
    [Abstract] [Full Text] [Related]

  • 8. Edotecarin: a novel topoisomerase I inhibitor.
    Saif MW, Diasio RB.
    Clin Colorectal Cancer; 2005 May 01; 5(1):27-36. PubMed ID: 15929804
    [Abstract] [Full Text] [Related]

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 10. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.
    Cancer Chemother Pharmacol; 2010 Jul 15; 66(2):269-76. PubMed ID: 19904537
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin.
    Sunami S, Nishimura T, Nishimura I, Ito S, Arakawa H, Ohkubo M.
    J Med Chem; 2009 May 28; 52(10):3225-37. PubMed ID: 19397324
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
    Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y.
    Cancer Chemother Pharmacol; 2002 Mar 28; 49(3):211-6. PubMed ID: 11935213
    [Abstract] [Full Text] [Related]

  • 13. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K, Tanaka Y, Tominaga T.
    Clin Cancer Res; 2001 Apr 28; 7(4):1079-86. PubMed ID: 11309360
    [Abstract] [Full Text] [Related]

  • 14. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H.
    Cancer Lett; 2007 Jan 08; 245(1-2):242-51. PubMed ID: 16540233
    [Abstract] [Full Text] [Related]

  • 15. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.
    Clin Cancer Res; 2009 Jul 15; 15(14):4649-64. PubMed ID: 19567590
    [Abstract] [Full Text] [Related]

  • 16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 15; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
    Menon K, Alvarez E, Forler P, Phares V, Amsrud T, Shih C, Al-Awar R, Teicher BA.
    Cancer Chemother Pharmacol; 2000 Jan 15; 46(2):142-9. PubMed ID: 10972484
    [Abstract] [Full Text] [Related]

  • 19. Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner.
    Egawa T, Kubota T, Furukawa T, Otani Y, Watanabe M, Furukawa T, Kumai K, Kitajima M.
    Anticancer Res; 2001 Jan 15; 21(4A):2597-600. PubMed ID: 11724327
    [Abstract] [Full Text] [Related]

  • 20. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON, Rais R, Naguib FN, el Kouni MH.
    Cancer Chemother Pharmacol; 2012 Jun 15; 69(6):1449-55. PubMed ID: 22373605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.